Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

aTYR PHARMA (ATYR) Operating Expenses (2019 - 2025)

aTYR PHARMA (ATYR) has disclosed Operating Expenses for 7 consecutive years, with $80.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Operating Expenses rose 9547.07% year-over-year to $80.5 million, compared with a TTM value of $77.8 million through Dec 2025, up 51.17%, and an annual FY2025 reading of $77.8 million, up 2099.41% over the prior year.
  • Operating Expenses was $80.5 million for Q4 2025 at aTYR PHARMA, up from -$999000.0 in the prior quarter.
  • Across five years, Operating Expenses topped out at $80.5 million in Q4 2025 and bottomed at -$43.8 million in Q4 2023.
  • Average Operating Expenses over 5 years is $10.8 million, with a median of $11.4 million recorded in 2021.
  • The sharpest move saw Operating Expenses tumbled 339.07% in 2023, then soared 9547.07% in 2025.
  • Year by year, Operating Expenses stood at $8.6 million in 2021, then soared by 112.22% to $18.3 million in 2022, then crashed by 339.07% to -$43.8 million in 2023, then soared by 98.06% to -$852000.0 in 2024, then skyrocketed by 9547.07% to $80.5 million in 2025.
  • Business Quant data shows Operating Expenses for ATYR at $80.5 million in Q4 2025, -$999000.0 in Q3 2025, and -$781000.0 in Q2 2025.